Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Revenue (2016 - 2025)

Historic Revenue for Fortress Biotech (FBIO) over the last 12 years, with Q3 2025 value amounting to $17.6 million.

  • Fortress Biotech's Revenue rose 2052.09% to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.3 million, marking a year-over-year decrease of 31.68%. This contributed to the annual value of $57.7 million for FY2024, which is 3175.61% down from last year.
  • Per Fortress Biotech's latest filing, its Revenue stood at $17.6 million for Q3 2025, which was up 2052.09% from $16.4 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Revenue registered a high of $34.8 million during Q3 2023, and its lowest value of $11.6 million during Q1 2021.
  • Over the past 5 years, Fortress Biotech's median Revenue value was $16.5 million (recorded in 2022), while the average stood at $17.5 million.
  • As far as peak fluctuations go, Fortress Biotech's Revenue skyrocketed by 12253.3% in 2021, and later plummeted by 5790.46% in 2024.
  • Over the past 5 years, Fortress Biotech's Revenue (Quarter) stood at $18.3 million in 2021, then fell by 10.24% to $16.4 million in 2022, then increased by 21.59% to $19.9 million in 2023, then dropped by 24.2% to $15.1 million in 2024, then rose by 16.61% to $17.6 million in 2025.
  • Its Revenue was $17.6 million in Q3 2025, compared to $16.4 million in Q2 2025 and $13.1 million in Q1 2025.